MedTrace Logo

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

NCT00121147 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2006-02-24

No results posted yet for this study

Summary

The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.

Conditions

Interventions

DRUG

Travatan

DRUG

Azopt

DRUG

Alphagan P

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • Hermann Eye Center

    lead OTHER

Principal Investigators

  • Robert M Feldman, M.D. · Hermann Eye Fund / University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-09-30
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00121147 on ClinicalTrials.gov